In the News
Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
July 28, 2020 — Alzheimer’s disease gets better biomarkers seemingly every year. Researchers found that a Lilly blood test can discern Alzheimer’s disease from other brain disease. The blood test looked at increased levels of a protein called p-tau, which builds up in Alzheimer’s disease, but not with normal age. This is a great find, although the field’s concern is that diagnostic tests are significantly ahead of therapeutic treatments. For now, this test will certainly help trials for both preventative and slightly symptomatic. Being able to differentiate people at risk of the disease will very much help our clinical trials. Once these tests are widely available, it will also help eliminate the current under-diagnosis of AD.ANA is proud to partner with Lilly in the development of Donanemab. Please see here for more information about this exciting clinical trial.
Alzheimer’s disease drug development pipeline: 2020
July 16, 2020 — “Alzheimer’s disease (AD) is a growing public health concern affecting millions of patients worldwide and costing billions of dollars annually. We review the pipeline of drugs and biologics in clinical trials for the treatment of AD.”
Butler Hospital among first in U.S. to launch new study of promising Alzheimer’s treatment
July 15, 2020 — “AHEAD 3-45, a new clinical study of a treatment aimed at preventing cognitive decline in people with preclinical Alzheimer’s Disease, has been launched in the United States, and Butler Hospital’s Memory and Aging Program is among the first U.S. study sites to begin screening potential participants.”